Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Prepaid Assets (2018 - 2025)

Historic Prepaid Assets for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $22.2 million.

  • 10x Genomics' Prepaid Assets rose 1441.52% to $22.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $22.2 million, marking a year-over-year increase of 1441.52%. This contributed to the annual value of $22.2 million for FY2025, which is 1441.52% up from last year.
  • As of Q4 2025, 10x Genomics' Prepaid Assets stood at $22.2 million, which was up 1441.52% from $19.2 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Prepaid Assets ranged from a high of $25.6 million in Q1 2025 and a low of $13.3 million during Q2 2021
  • Moreover, its 5-year median value for Prepaid Assets was $19.0 million (2022), whereas its average is $18.4 million.
  • In the last 5 years, 10x Genomics' Prepaid Assets surged by 10352.31% in 2021 and then tumbled by 1000.15% in 2024.
  • 10x Genomics' Prepaid Assets (Quarter) stood at $13.9 million in 2021, then grew by 19.3% to $16.6 million in 2022, then increased by 13.34% to $18.8 million in 2023, then grew by 3.31% to $19.4 million in 2024, then increased by 14.42% to $22.2 million in 2025.
  • Its Prepaid Assets stands at $22.2 million for Q4 2025, versus $19.2 million for Q3 2025 and $20.4 million for Q2 2025.